Avelumab: Another Immunotherapy for Bladder Cancer – Medscape
Medscape |
Avelumab: Another Immunotherapy for Bladder Cancer
Medscape Another immunotherapy has been approved for use in urothelial cancer, the most common type of bladder cancer, in the United States. Avelumab (Bavencio, EMD Serono INc), which is a programmed cell death ligand–1 (PD L1) inhibitor, has been approved … Avelumab Granted Accelerated Approval for Bladder Cancer |
